Roger von Moos1, Michael Mark1, Karin Ribi2, Beat Thürlimann3, Corinne Schär4, Daniel Dietrich4, Richard Cathomas1, Ursina Zürrer-Härdi5, Thomas von Briel6, Sandro Anchisi7, Pierre Bohanes8, Veronika Blum9, Philippe von Burg10, Meinrad Mannhart11, Clemens B Caspar12. 1. Kantonsspital Graubünden, Chur, Switzerland. 2. International Breast Cancer Study Group (IBCSG), Bern, Switzerland. karin.ribi@ibcsg.org. 3. Kantonsspital St. Gallen, St. Gallen, Switzerland. 4. Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland. 5. Kantonsspital Winterthur, Winterthur, Switzerland. 6. Klinik Hirslanden, Zürich, Switzerland. 7. Hôpital du Valais, Sion, Switzerland. 8. Centre de Chimiothérapie Anti-Cancéreuse, Lausanne, Switzerland. 9. Kantonsspital Luzern, Luzern, Switzerland. 10. Burgerspital Solothurn, Solothurn, Switzerland. 11. Andreasklinik Cham Zug, Cham, Switzerland. 12. Kantonsspital Baden, Baden, Switzerland.
Abstract
BACKGROUND: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. METHODS: This real world, cross-sectional study enrolled patients over a 3-month period through oncologists across Switzerland. Patients were ≥ 18 years, had solid tumors and at least one bone metastasis, and received routine care for bone metastases. Physicians provided data on BTA-related practices, risk of bone complications and BTA regimen. Patients completed questionnaires about pain (BPI-SF), general and bone pain-related QoL (FACT-G, FACT-BP) and treatment satisfaction (FACIT-TS-G). RESULTS: Eighteen sites recruited 417 patients. Based on the FACT-BP, 42% of the patients indicated not having bone pain. According to the BPI-SF, 28% reported no, 43% mild, 14% moderate, and 15% severe pain, respectively. Patients not treated with a BTA had better overall QoL (FACT-G: p = 0.031) and bone pain-related QoL (FACT-BP, p = 0.007) than those treated with a BTA. All pain and other QoL scales did not differ between groups. Patients perceived at 'low risk of bone complications' by their physician not receiving a BTA reported less pain and better QoL than those considered at 'low risk' but receiving BTA treatment or those considered at 'high risk' regardless of BTA treatment. Overall satisfaction with the treatment was good; almost 50% of patients reporting that they were completely satisfied. CONCLUSIONS: Overall, pain and QoL did not differ according to BTA treatment or physicians' risk perception. Patient with low risks not receiving BTA treatment reported least pain and highest QoL scores. These results may suggest that treating physicians assess bone complication risk appropriately and treat patients accordingly, but they need to be confirmed by objective determination of longitudinal skeletal complication risk.
BACKGROUND: Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (QoL) is limited. METHODS: This real world, cross-sectional study enrolled patients over a 3-month period through oncologists across Switzerland. Patients were ≥ 18 years, had solid tumors and at least one bone metastasis, and received routine care for bone metastases. Physicians provided data on BTA-related practices, risk of bone complications and BTA regimen. Patients completed questionnaires about pain (BPI-SF), general and bone pain-related QoL (FACT-G, FACT-BP) and treatment satisfaction (FACIT-TS-G). RESULTS: Eighteen sites recruited 417 patients. Based on the FACT-BP, 42% of the patients indicated not having bone pain. According to the BPI-SF, 28% reported no, 43% mild, 14% moderate, and 15% severe pain, respectively. Patients not treated with a BTA had better overall QoL (FACT-G: p = 0.031) and bone pain-related QoL (FACT-BP, p = 0.007) than those treated with a BTA. All pain and other QoL scales did not differ between groups. Patients perceived at 'low risk of bone complications' by their physician not receiving a BTA reported less pain and better QoL than those considered at 'low risk' but receiving BTA treatment or those considered at 'high risk' regardless of BTA treatment. Overall satisfaction with the treatment was good; almost 50% of patients reporting that they were completely satisfied. CONCLUSIONS: Overall, pain and QoL did not differ according to BTA treatment or physicians' risk perception. Patient with low risks not receiving BTA treatment reported least pain and highest QoL scores. These results may suggest that treating physicians assess bone complication risk appropriately and treat patients accordingly, but they need to be confirmed by objective determination of longitudinal skeletal complication risk.
Entities:
Keywords:
Bone metastases; Bone-pain related quality of life; Bone-targeting agents; Non-interventional; Patient-reported pain; Patterns of care
Authors: Donald L Patrick; Charles S Cleeland; Roger von Moos; Lesley Fallowfield; Rachel Wei; Katarina Öhrling; Yi Qian Journal: Support Care Cancer Date: 2014-12-23 Impact factor: 3.603
Authors: John D Peipert; Jennifer L Beaumont; Rita Bode; Dave Cella; Sofia F Garcia; Elizabeth A Hahn Journal: Qual Life Res Date: 2013-09-24 Impact factor: 4.147
Authors: Charles S Cleeland; Jean-Jacques Body; Alison Stopeck; Roger von Moos; Lesley Fallowfield; Susan D Mathias; Donald L Patrick; Mark Clemons; Katia Tonkin; Norikazu Masuda; Allan Lipton; Richard de Boer; Stefania Salvagni; Celia Tosello Oliveira; Yi Qian; Qi Jiang; Roger Dansey; Ada Braun; Karen Chung Journal: Cancer Date: 2012-09-05 Impact factor: 6.860
Authors: Roger von Moos; Jean-Jacques Body; Blair Egerdie; Alison Stopeck; Janet E Brown; Danail Damyanov; Lesley J Fallowfield; Gavin Marx; Charles S Cleeland; Donald L Patrick; Felipe G Palazzo; Yi Qian; Ada Braun; Karen Chung Journal: Support Care Cancer Date: 2013-08-22 Impact factor: 3.603
Authors: Madeleine T King; David Cella; David Osoba; Martin Stockler; David Eton; Joanna Thompson; Amy Eisenstein Journal: Patient Relat Outcome Meas Date: 2010-09-23
Authors: Charles Cleeland; Roger von Moos; Mark S Walker; Yuanyuan Wang; Jianqing Gao; Mariana Chavez-MacGregor; Alexander Liede; Jorge Arellano; Arun Balakumaran; Yi Qian Journal: Support Care Cancer Date: 2016-03-29 Impact factor: 3.603
Authors: Roger von Moos; Jean-Jacques Body; Alex Rider; Jonathan de Courcy; Debajyoti Bhowmik; Francesca Gatta; Guy Hechmati; Yi Qian Journal: J Bone Oncol Date: 2017-11-24 Impact factor: 4.072
Authors: Michael Mark; Beat Thürlimann; Karin Ribi; Corinne Schär; Daniel Dietrich; Richard Cathomas; Ursina Zürrer-Härdi; Thomas von Briel; Sandro Anchisi; Pierre Bohanes; Veronika Blum; Philipp von Burg; Meinrad Mannhart; Clemens B Caspar; Roger von Moos Journal: J Bone Oncol Date: 2019-12-16 Impact factor: 4.072